Ligand Pharmaceuticals (LGND) Cash from Financing Activities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$14.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$14.1 million, down 197.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $418.8 million (up 422.16% YoY), and the FY2025 annual result was $428.2 million, up 340.83% from the prior year.
• Cash from Financing Activities came in at -$14.1 million for Q1 2026 at Ligand Pharmaceuticals, down from $8.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $409.6 million in Q3 2025 to a low of -$170.4 million in Q1 2022.
• The 5-year median for Cash from Financing Activities is $3.3 million (2023), against an average of $10.3 million.
• Across the five-year window, Cash from Financing Activities sank 10504.94% in 2022 and jumped 1671.87% in 2024, its largest moves.
• Ligand Pharmaceuticals' Cash from Financing Activities stood at -$5.3 million in 2022, then surged by 200.32% to $5.3 million in 2023, then jumped by 283.59% to $20.4 million in 2024, then sank by 59.14% to $8.3 million in 2025, then sank by 269.66% to -$14.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$14.1 million (Q1 2026), $8.3 million (Q4 2025), and $409.6 million (Q3 2025), per Business Quant data.